Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024
Yescarta is First CAR T-cell therapy to receive NCCN treatment guideline category 1 recommendation --
The launch of medical cannabis products resulted from an agreement between the two companies signed in 2021
Primarily set up to address the Covid-19 emergency, the WHO technology transfer hub has the potential to expand manufacturing capacity for other products as well, including treatments, and target other priorities such as malaria, HIV and cancer
Celerity Pharmaceuticals uses Biocon Biologics’ insulin drug substance to develop the product
Through this consortium, Lonza will collaborate with other industry leaders to advance the research and development of inhalation technologies
Through this partnership, Premas will connect with genomics labs to provide automated NGS solutions
The plant is scheduled to come on stream in September 2024
The new structure further transitions the Health Care business line into a system solutions partner for the pharmaceutical and biotech industries
No new studies have been requested
Subscribe To Our Newsletter & Stay Updated
